Analysts See $3.97 EPS for Allergan plc (AGN)

October 14, 2018 - By Peter Erickson

Allergan plc (NYSE:AGN) LogoInvestors sentiment increased to 2 in 2018 Q2. Its up 1.50, from 0.5 in 2018Q1. It increased, as 2 investors sold Allergan plc shares while 1 reduced holdings. 3 funds opened positions while 3 raised stakes. 69,030 shares or 10.85% less from 77,429 shares in 2018Q1 were reported.
Callahan Advsrs Ltd Com has 0.5% invested in Allergan plc (NYSE:AGN) for 15,343 shares. Grassi Investment Mngmt invested in 1.16% or 43,335 shares. Whittier Tru invested 0.02% of its portfolio in Allergan plc (NYSE:AGN). Cubic Asset Mngmt Limited Company stated it has 2,130 shares. Mitchell Mcleod Pugh And Williams accumulated 3,935 shares. Staley Cap Advisers invested in 1,400 shares or 0.02% of the stock. Gemmer Asset Limited Liability holds 117 shares or 0.01% of its portfolio. Whittier Com Of Nevada Inc reported 0% in Allergan plc (NYSE:AGN).

Analysts expect Allergan plc (NYSE:AGN) to report $3.97 EPS on November, 7.They anticipate $0.18 EPS change or 4.34 % from last quarter’s $4.15 EPS. AGN’s profit would be $1.35B giving it 11.54 P/E if the $3.97 EPS is correct. After having $4.42 EPS previously, Allergan plc’s analysts see -10.18 % EPS growth. The stock increased 0.58% or $1.06 during the last trading session, reaching $183.28. About 2.15M shares traded or 19.25% up from the average. Allergan plc (NYSE:AGN) has declined 17.68% since October 14, 2017 and is downtrending. It has underperformed by 33.30% the S&P500.

Allergan plc (NYSE:AGN) Ratings Coverage

Among 11 analysts covering Allergan (NYSE:AGN), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Allergan had 16 analyst reports since April 16, 2018 according to SRatingsIntel. The firm has “Neutral” rating by Cantor Fitzgerald given on Tuesday, May 1. Cowen & Co maintained Allergan plc (NYSE:AGN) on Monday, April 16 with “Buy” rating. Wells Fargo maintained the shares of AGN in report on Thursday, August 23 with “Outperform” rating. Bank of America maintained it with “Buy” rating and $209 target in Tuesday, May 1 report. The stock of Allergan plc (NYSE:AGN) earned “Overweight” rating by Morgan Stanley on Thursday, August 23. On Thursday, May 31 the stock rating was maintained by Piper Jaffray with “Hold”. The firm has “Buy” rating by Bank of America given on Tuesday, June 12. The rating was maintained by Cantor Fitzgerald on Monday, May 7 with “Hold”. The firm has “Outperform” rating by Credit Suisse given on Thursday, May 3. The firm has “Hold” rating given on Wednesday, May 30 by Mizuho.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $62.21 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women??s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer??s disease.

More notable recent Allergan plc (NYSE:AGN) news were published by: which released: “Allergan announces FDA acceptance of supplemental new drug application for VRAYLAR” on September 26, 2018, also with their article: “FDA OKs Paratek’s sarecycline for acne” published on October 02, 2018, published: “HighTide’s HTD1801 Fast Track’d for PSC” on September 27, 2018. More interesting news about Allergan plc (NYSE:AGN) were released by: and their article: “Allergan to Report Third Quarter 2018 Earnings and Host Conference Call and Webcast” published on October 01, 2018 as well as‘s news article titled: “JMP: Changing Competitive Landscape Makes Revance Less Appealing” with publication date: September 17, 2018.

Allergan plc (NYSE:AGN) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.